Tsveta Milanova Biography and Net Worth

Chief Commercial Officer of Agios Pharmaceuticals

Ms. Milanova joined Agios as chief commercial officer in January 2023, bringing two decades of experience in commercial leadership and global market access in the biopharmaceutical industry. She spent five years at Alexion in high-impact commercial and market access roles, including senior vice president, head of U.S. commercial; senior vice president, global commercial strategy; and senior vice president, global value, access and policy. Prior to Alexion, she spent more than ten years at Celgene in roles of increasing responsibility in global pricing and market access, most recently as global head, pricing and market access for the hematology and oncology division. She holds a master of science (MSc) degree in international health policy and health economics from the London School of Economics, a master of science (MSc) degree in pharmacy from the Medical University of Sofia, Bulgaria and is a graduate of Harvard’s Advanced Management Program.

What is Tsveta Milanova's net worth?: The estimated net worth of Tsveta Milanova is at least $1.02 million as of June 24th, 2025. Ms. Milanova owns 26,122 shares of Agios Pharmaceuticals stock worth more than $1,023,721 as of July 15th. This net worth evaluation does not reflect any other assets that Ms. Milanova may own. Learn More about Tsveta Milanova's net worth.
How do I contact Tsveta Milanova?: The corporate mailing address for Ms. Milanova and other Agios Pharmaceuticals executives is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. Agios Pharmaceuticals can also be reached via phone at (617) 649-8600 and via email at [email protected]. Learn More on Tsveta Milanova's contact information.
Has Tsveta Milanova been buying or selling shares of Agios Pharmaceuticals?: Tsveta Milanova has not been actively trading shares of Agios Pharmaceuticals during the past quarter. Most recently, Tsveta Milanova sold 2,770 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a transaction totalling $92,905.80. Following the completion of the sale, the insider now directly owns 26,122 shares of the company's stock, valued at $876,131.88. Learn More on Tsveta Milanova's trading history.
Who are Agios Pharmaceuticals' active insiders?: Agios Pharmaceuticals' insider roster includes Carman Alenson (Insider), Jonathan Biller (CFO & Head of Corp. Affairs ), Christopher Bowden (Insider), James Burns (https://www.linkedin.com/in/jackie-fouse-a90b811aa), Jacqualyn Fouse (CEO & Director ), Jacqualyn Fouse (Director), Sarah Gheuens (Chief Medical Officer, Head of R&D), Brian Goff (CEO), Cecilia Jones (CFO), Tsveta Milanova (Chief Commercial Officer), Darrin Miles (Insider), and David Scadden (Director). Learn More on Agios Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Agios Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 70,497 shares worth more than $2,512,089.18. The most recent insider tranaction occured on July, 10th when Director David Scadden sold 1,400 shares worth more than $56,000.00. Insiders at Agios Pharmaceuticals own 4.9% of the company. Learn More about insider trades at Agios Pharmaceuticals.
Information on this page was last updated on 7/10/2025.

Tsveta Milanova Insider Trading History at Agios Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/24/2025	Sell	2,770	$33.54	$92,905.80	26,122
1/6/2025	Sell	2,804	$32.18	$90,232.72	18,906
1/5/2024	Sell	2,902	$22.32	$64,772.64	9,404

Tsveta Milanova Buying and Selling Activity at Agios Pharmaceuticals

Agios Pharmaceuticals Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $39.19

$38.70

$39.79

50 Day Range

MA: $33.12

$27.32

$39.53

2 Week Range

Now: $39.19

$23.42

$62.58

Volume

699,040 shs

Average Volume

657,355 shs

Market Capitalization

$2.27 billion

P/E Ratio

3.49

Dividend Yield

N/A

Beta

0.73